# A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

> **NCT02261467** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 421 (actual)

## Conditions studied

- Forehead Rhytides
- Glabellar Rhytides

## Interventions

- **BIOLOGICAL:** OnabotulinumtoxinA
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT02261467
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-21
- **Primary completion:** 2015-06-04
- **Final completion:** 2016-04-26
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2019-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02261467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02261467, "A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02261467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*